Compare CRDL & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | POAS |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 85.9M |
| IPO Year | N/A | 2025 |
| Metric | CRDL | POAS |
|---|---|---|
| Price | $1.07 | $6.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 373.9K | ★ 957.4K |
| Earning Date | 03-30-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $128,328.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $2.90 |
| 52 Week High | $1.59 | $7.40 |
| Indicator | CRDL | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 71.81 |
| Support Level | $0.95 | $5.86 |
| Resistance Level | $1.04 | $7.40 |
| Average True Range (ATR) | 0.05 | 0.57 |
| MACD | 0.01 | 0.31 |
| Stochastic Oscillator | 76.47 | 72.71 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.